NASDAQ •
Healthcare •
Diagnostics & Research •
Quote as of 06/03/2026 16:00
Company Profile
IndustryDiagnostics & Research
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,129.42 mln
Float62.47 mln
Earnings Date08/11/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-1.68
Likely manipulated
1-Year Forecast
10.86
Fairly priced
Relative Strength
97
/ 100
Top performer
Debt / Equity
0.15
Very low leverage
ROE
-44.01
Deeply negative
Business Description
Personalis is a US-based genomics company that develops advanced cancer testing products and services for patients, healthcare providers, and life sciences organizations worldwide. Its core offerings include blood-based tests that detect traces of cancer remaining after treatment, monitor how well a therapy is working, and flag signs of recurrence, as well as tissue-based tests that give a detailed picture of a tumor to guide treatment decisions. The company also supports pharmaceutical and diagnostic firms with genomic sequencing for research, drug development, and clinical trials, and has a partnership with Tempus AI focused on colorectal cancer patients. Founded in 2011 and headquartered in Fremont, California, Personalis serves a broad range of customers from individual patients and physicians to universities, government agencies, and major drug makers.
